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Prevalence of chronic ocular complications in Stevens-Johnson Syndrome 
and Toxic Epidermal Necrolysis 
Research question: 
What are the degrees of involvement and the long-term complications of 
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) on 
the different external ocular structures? 
Investigators: 
Dr Lourens van Zyl (Principle investigator) 
Dr Karin Lecuona (Supervisor) 
Abstract: 
Objectives: The main objective of the study is to identify and grade the 
severity of chronic ocular complications in patients who were treated for SJS 
and TEN at Groote Schuur Hospital. The secondary objective is to identify 
patients who need referrals to specialist ophthalmic clinics for treatable ocular 
complications of SJS and TEN. 
Design: The design of the study is a prospective cross-sectional study of 
consecutive patients treated at Groote Schuur Hospital for SJS and TEN. 
Setting: Patients will be examined and data will be gathered in the Eye Clinic 
at Groote Schuur Hospital. 
Study participants: Patients who were diagnosed with SJS or TEN and treated 




Patients with a dermatological diagnosis of SJS or TEN who were 
admitted and treated at Groote Schuur Hospital. 
- Patients with a diagnosis of SJS or TEN for six months or longer. 
- Both eyes of patients will be included, even if there is no clinical 
evidence of involvement, as it will form part of the statistics. 
Exclusion criteria: 
Patients with previous eyelid or ocular surface surgery. 
Patients with a follow-up of less than six months. 
Outcome measures: 
The degree of involvement of the cornea, conjunctiva and eyelids will be 
assessed according to the following classifications: 
1. Corneal 
• superficial punctate keratopathy (SPK) 
• epithelial defects 








• symblepharon formation 
3. Eyelid 
• trichiasis 
• mucocutaneous junction involvement 
• meibomian gland involvement 
• punctal damage. 
Ocular abnormalities unrelated to ocular surface disorders will be recorded, 
including cataracts, glaucoma, retinal diseases and scleritis. Their presence, 
absence or inability to be diagnosed because of ocular surface abnormalities 
will be recorded. 
Due to the high prevalence of HIV in our population, we will compare the 
ocular complications resulting from SJS and TEN on HIV-positive and HIV-
negative patients. 
The outcome measures will include: 
• What percentage of patients have no external ocular involvement? 
• What percentage of patients have external ocular involvement, and to 
what extent? 
• What percentage of patients are legally blind (presenting visual acuity of 
less than 3/60 in the better eye) due to SJS and TEN? 
Follow up: all patients with ocular involvement will be referred to appropriate 
specialist clinics for treatment. Minor abnormalities of treatable consequences 
will be referred to day hospitals for further treatment. All patients that are blind 
due to SJS or TEN will receive referrals to Social Services for disability grants 
and to the League of Friends of the Blind (LOFOB) for rehabilitation. 
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Specific aims: 
The aim of the study is to identify the proportion of patients who have 
developed chronic ophthalmic complications due to SJS or TEN. Further, we 
want to grade the extent and severity of chronic ocular manifestations to 
better predict the visual prognosis and treatment needed for patients with 
ocular involvement. As there are no universal classifications of chronic ocular 
complications following SJS and TEN, previous studies cannot be compared. 
We aim to use the same classification in our study according to the latest 
published classification system. 1 The secondary aim is to identify treatable 
consequences that can prevent a severe decrease in vision. 
Background and significance: 
SJS and TEN is a complex immunological syndrome that is characterised by 
mucocutaneous blistering of the skin and at least two mucous membranes.1•2•3 
The so-called 'target lesions' and blistering of the skin are pathonomonic of 
the disease.4 Mucosal blisters develop in the mouth and nose, and these 
usually rupture and form erosions. Haemorrhagic crusting of the lips is a 
characteristic sign, but genital involvement is more uncommon. Blistering is 
usually transient and may be widespread and associated with haemorrhage 
and necrosis. Healing occurs within four weeks, usually leaving a pigmented 
scar. Sloughing of the epidermis is widespread in TEN.3•4 
SJS and TEN have the same signs and symptoms, but they differ in severity, 
with TEN involving blistering and sloughing of skin of more than 30% of the 
body's surface. 
Males are affected more than females, and the disease can occur at any 
age.4 
The disease is thought to be either a delayed hypersensitivity reaction to 
certain medications or a response to epithelial cell antigens modified by drug 
exposure.3 Genetic predisposition may also playa part due to a genetically 
determined enzyme deficiency for the metabolites of certain medicines.2 The 
medicines most commonly associated with SJS and TEN are antibiotics 
(especially trimetroprim), analgesics, cold remedies NSAIDs, phenytoin, 
allupurinol and acetazolamide. 1 In the past decade, anti-retroviral treatment 
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has surpassed most other medicines as the main culprit in the cause of SJS 
and TEN in developing countries.4 
As symptoms develop up to three weeks after exposure, the precipitating 
cause cannot be identified with certainty in 50% of cases.3 
It is reported that approximately 27-80% of hospitalised patients with SJS and 
TEN develop acute ocular complications. 1 Although severe corneal damage 
can result from the acute effects of the disease, corneal opacification usually 
results from chronic complications.3 Corneal micro-trauma due to 
keratinisation of the eyelid margin and a variable degree of meibomian gland 
dysfunction are the main causes of a decrease in visual acuity.2 
While the majority of patients have minimal long-term ocular involvement, it is 
known that some patients may present with severe ocular complications that 
result in visual impairment and blindness. The risk factors for poor outcomes 
are not known. It is thought that suppression of inflammation in the acute 
stage might reduce corneal damage scarring due to blink-related micro-
trauma caused by conjunctival and tarsal scarring.2,3 
Most studies about chronic ocular complications in SJS and TEN only include 
study subjects with known ocular involvement. In addition, most studies are 
retrospective and use a non-comparative grading system. 
In this study, we will use a newly published grading system developed 
specifically to classify chronic ocular complications. This will be the first 
published study relating to ocular complications due to SJS and TEN in Africa. 
Research Plan: 
Patients who have a dermatological diagnosis with SJS or TEN will be 
identified and recruited from a database of patients provided by the 
Department of Dermatology at Groote Schuur Hospital. Only patients with a 
follow-up of more than six months after the onset of SJS or TEN will be 
included in the study. Identified patients will be contacted by the ward D4 
secretary to follow up in either ward D4 or the ophthalmology out-patients 
department on a given date. Patients will be informed of the study and will 
need to sign consent forms for their data to be used in the study. A one-off 
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visit will be necessary to obtain all data. Study participants who had SJS or 
TEN between 2003 and 2009 will be recruited for the study. 
The symptoms and ocular findings will be recorded on an itemised collection 
form. An assessment of the presenting and pinhole Snellen visual acuity will 
be performed. A slit lamp examination, including fluorescein staining, will be 
done on both eyes to examine the external ocular structures. Tonometry will 
be performed on all patients. Tear break-up time will be added to the 
measurements, and dry eye symptoms will be assessed. 
Data obtained from the ocular examination will be divided into complications 
of the eyelids, conjunctiva and cornea, and the data will be recorded on the 
itemised patient chart. The disease severity will include 13 components that 
are graded on a scale of 0 to 3 to give an overall score from 0 to 39, with 39 
representing the most severely affected eyes. Data for patients without ocular 
involvement will also be recorded. 
Drug history, HIV status and CD4 will be obtained from the dermatology 
records. A drug will be considered a possible etiological agent if it has been 
taken within two weeks of the onset of disease. 
Patients requiring further referrals will be referred to the appropriate specialist 
clinic (e.g. cornea clinic) or day hospital. 
Data will be captured in a Microsoft Excel spreadsheet and analysed using 
Stata. Patient characteristics and ophthalmological characteristics with means 
and median properties will be analysed using with aT-test and properties with 
a chi2 test. 
Photographs will be taken for publication purposes. Photos will only be taken 
of patients' eyes and the anterior structures in order to protect patients' 
identities. No names will be used in the study; only hospital numbers will be 
used to identify patients. 
Ethics: 
Ethical approval will be obtained from the University of Cape Town Faculty of 
Health Sciences Ethics Committee. 
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Reporting: 
A paper reporting the findings of the study will be submitted to a peer-
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Discomforts and risks: 
Patients may be inconvenienced. A one-off 20-minute examination will be 
necessary to capture the data. The only discomfort that was identified might 
be the travel to the hospital; in the case of the visually impaired, an escort 
might be needed. Visits will be charged according to the U PFS. As most 
patients who are treated for TENS and SJS at Groote Schuur Hospital are 
classified as H1, they will not be required to pay for the clinic visit. We intend 
to compensate each patient with R 150 to cover travel expenses. A budget of 
R7500 will be required, and funding will be obtained from the University of 
Cape Town Research Fund. Files will be gathered from the records 
department, and patients will be informed to attend at either 04 or the 
Ophthalmology out-patients department. 
Benefits: 
• Identify and grade the long-term complications of SJS and TEN. 
• Identify the risk of developing ophthalmic complications if a patient suffers 
from SJS or TEN. 
• Identify patients who will benefit from any secondary intervention to 
improve their current visual acuity. 
• Refer patients to appropriate specialist clinics or day hospitals where 
required. 
Financial risks: 
Participants will not incur any financial risk. 
Financial benefits: 
We intend to compensate each participant for their travel expenses, as this 
study is not part of the standard care of the participants. Patients will be paid 
a fee to travel to and from the hospital. An amount of R150 per patient is 
required and, in the case of a patient travelling from outside the metro pole of 
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Cape Town, an amount of R200 is required. We wish to obtain sponsorship 
from the University of Cape Town research grants. 
Conflict of interest: 
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The objective of the literature review is to examine whether sufficient literature 
has been published on the incidence of chronic complications of Stevens-
Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as there has 
been an increase in the number of patients who present late with ocular 
complications secondary to SJS and TEN. 
Another objective is to gather information on the chronic ocular complications 
of SJS or TEN. Specifically, I will examine the chronic complications; most 
patients are referred to the Ophthalmology Department several months after 
they have been treated for SJS or TEN. Long after the dermatological disease 
has ceased, these patients present mainly with chronic complications. Thus, I 
will examine the natural history of the disease in the chronic stages. 
Further, I will observe whether there is a difference in the prevalence and 
severity of the eye disease in a setting where most of the patients are HIV-
positive, compared to studies conducted in countries with a low prevalence of 
HIV. 
I will examine studies and whether their classification systems can be used in 
a comparative study in an African setting, as there is no universal 
classification system of ocular complications in SJS and TEN. 
Method: 
A Pub-Med search was conducted using the Pub-Med search engine. 
The keywords used were: chronic-eye-complications Stevens-Johnson 
syndrome Toxic epidermal necrolysis. Acronyms such as SJS and TEN and 
synonyms such as 'ocular' and 'long term' were used. A result with Erythema 
Multiforme (EM) was not used because it was regarded as a separate disease 
entity. The inclusion criteria were that the publication must only contain 
literature on chronic complications. Only English language articles were used 
and, where an article was not in English, the translated abstract was used. 
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Results: 
The article that I found most relevant was by Sotozono et al. The paper 
evaluates the extent of chronic ocular manifestations after SJS and TEN, and 
it proposes a new grading system for the complications. 1 The study was 
conducted between 2003 and 2005, and it was a prospective multicentre case 
series done at three ophthalmic centres in Japan. Seventy-three patients (138 
eyes) were included in the study. They were referred with a confirmed 
diagnosis of SJS or TEN and had a confirmed history of chronic ocular 
disease for more than one year. Patients were excluded if they had 
undergone any ocular surface surgery in the past. All data and medical 
histories were captured on an itemised data collection form. The main 
outcome measures were broadly classified as corneal, conjunctival and eyelid 
complications. Thirteen components were graded from 0 to 3 depending on 
the severity of the complication, where 0 is equal to no involvement and 3 is 
severe involvement. 
The most commonly occurring complication was loss of the palisades of Vogt 
(POV) (114-eyes/82.6%). The second most common component was 
meibomian gland involvement (102 eyes/73.9%). The visual acuity in 53% of 
the study subjects was worse than 20/200. The severity of visual loss 
correlated with the severity of the corneal, eyelid and conjunctival 
involvement. Eyes with a higher total score for the three complications had 
poorer vision (p<0.0001). Multivariate regression analysis showed that 
corneal neovascularisation (p<0.0001), opacification (p<0.0001), 
keratinisation (p<0.0142) and cataracts (p<0.0375) significantly affected log 
MAR acuities. The authors describe a new grading system for the extent and 
severity of ocular involvement and conclude that it correlates significantly with 
the final visual outcome. 
This was the only prospective study conducted on patients with SJS and TEN 
with chronic ocular complications. 
One of the limitations of this study was that dry eye syndrome was not part of 
the classification system; whereas most other studies in the literature review 
included dry eye symptoms. In my experience, most patients presenting in the 
late stages have dry eye syndrome. This complication is caused by the known 
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fact that SJSfTEN destroys conjunctival goblet cells. These cells are important 
in the production of the mucus layer in the tear film, and they cause an 
evaporative type of dry eye syndrome. I included dry eye symptoms and 
added tear break-up time to the data collection form to be more comparable 
with other studies. 
Similar to my study, De Rojas and others from the Moorfields Cornea and 
External diseases service in London reported on the natural history of SJS 
and TEN, and they characterised patterns of chronic ocular disease.2 The 
study was a retrospective case study of 30 patients (60 eyes) between 1975 
and 2004. A limitation of this study was that data were collected from case 
notes retrospectively. All patients had a dermatological diagnosis of SJS and 
TEN. The principle outcome measure of the study was to identify and classify 
the patterns in chronic eye disease in SJS and TEN. The authors grouped the 
patterns of chronic ocular complications as follows: 
- Mild to moderate involvement: eyes with mild to moderate 
complications due to conjunctival scarring. These eyes have 
healthy corneas with no recurrent or progressive inflammation. 
- Severe involvement: eyes with severe complications resulting 
mainly from conjunctival scarring. There was no evidence of 
stem cell deficiency. These eyes were very dry with an opaque, 
vascularised and irregular surface. They had a stable epithelium 
and no evidence of conjunctival inflammation or progressive 
scarring. 
- Ocular surface disease: surface failure with evidence of stem 
cell deficiency occurring after the acute attack of SJS. 
- Recurrent inflammation: eyes with recurrent episodes of 
conjunctival inflammation without progressive scarring. 
- Scleritis: patients developing scleritis after the acute attack. 
- Mucus membrane pemphigoid: eyes with early or late 
conjunctival inflammation and leading to progressive scarring. 
The authors conclude that ocular disease following SJS and TEN is not 
limited to the complications of the acute phase illness, and that 
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ophthalmologists need to be aware of disease progression. Successful 
management of chronic ocular complications in SJS and TEN requires the 
identification of the different components of the disease for the prognosis of 
vision. Although this was a retrospective study, this conclusion confirmed 
what we were seeing clinically in the Outpatients department; namely, that 
patients with minimal ocular involvement in the acute phase presented with 
chronic ocular complications more than six months later. 
SJS and TEN as a disease entity itself does not cause visual loss; however, 
patients can present with severe visual loss and morbidity due to the 
dermatological disease. Oi Pascuale examined the correlation of corneal 
complications secondary to cicatricial eyelid pathologies in SJS and TEN. 3 
The study was a retrospective observational case study of 38 patients 
between 2002 and 2004 who had confirmed SJS or TEN. The inclusion 
criteria was known ocular complications from SJS and TEN, and the exclusion 
criterion was any ocular surface surgery before or after the acute attack. The 
main outcome measures were: floppy eyelids (graded as 1-3 depending on 
the severity) and cicatricial complications involving different locations of the 
ocular surface, such as lids (entropion), puncta (auto occlusion), lashes 
(trichiasis and districhiasis), lid margin (scar and keratinisation), meibomian 
gland metaplasia, symblepharon and bulbar conjuntiva (scarring with or 
without motility restriction). The severity of the cicatricial lid margin and tarsal 
pathologies was graded as mild, moderate or severe by reviewing 
photographs of the study participants. The corneal complications were also 
graded as mild (clear cornea with superficial punctate keratopathy (SPK)), 
moderate (corneal haze and peripheral corneal neovascularisation) and 
severe (central corneal haze or scarring with extensive neovascularisation). In 
all of the cases reviewed, keratinisation of the eyelids with meibomian 
dysfunction was observed. Floppy eyelids (95% confidence intervals (Cis), 
p=0.5), trichiasis (95% CI, p=0.2), partially occluded lacrimal puncta (95%, 
p=0.9), symblepharon (95%, p=0.5) and tear deficiency (95% CI, p=0.5) were 
not significantly correlated with corneal complications. However, there was a 
strong correlation between the extent of corneal complications and the eyelid 
margin and tarsal pathology (95% CI, p=0.006). The authors concluded that 
lid margin keratinisation and tarsal scarring with tear deficiency contribute to 
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corneal complications because of blink-related micro-trauma. In addition, SJS 
and TEN do not directly cause visual impairment; rather, it is due to the 
chronic complications of the disease. Although this was a retrospective study, 
it was useful because the authors studied photographs of patients' pathology 
to gather data. The data were therefore highly objective and reproducible. 
Kompella and others also examined ocular complications, aetiological factors 
and the management of these complications in patients with SJS.4 The 
retrospective study was conducted at a tertiary institution in India by reviewing 
the medical records of patients seen between 1987 and 1998. The details of 
the ocular exams were collected to determine a pattern of presentation, 
complications, treatment responses and outcomes. The ocular findings were 
divided into those involving eyelids, conjunctiva and cornea. Lid abnormalities 
included lid thickening, discharge, meibonitis, blepharitis, trichiasis, 
dystrichiasis, entropion, ectropion. Conjunctival pathologies included 
congestion, xerosis, symblepharon and ankyloblepharon. Corneal 
abnormalities included SPK, thinning, scarring, vascularisation, keratinisation 
and infectious keratitis. All 95 participants had bilateral and symmetric 
disease. The average time of presentation to the Institute was one year after 
the acute phase. Lid abnormalities were observed in 91.5% of patients, while 
96.8% had conjunctival abnormalities and 97.8% had corneal complications. 
A best-corrected visual acuity of 6/12 or better was reported in 33.6% of 
patients, while 17% had acuity between 6/12 and 6/60, and 41.05% had a 
visual acuity of 6/60 or less. The authors concluded that SJS and TEN is an 
important cause of ocular morbidity and visual loss, which affect the quality of 
life. The authors pointed out that few treatment options were available for 
chronic complications, and that advances in immune modulation techniques 
are required to prevent many chronic complications. 
Yip and others also tried to identify predictors for the development of late 
complications in a study conducted in Singapore.5 They noted that most 
studies on ocular complications due to SJS and TEN were conducted on 
Caucasian patients. They stated that there are genetic differences in drug 
metabolism, and that the severity of the disease on the eyes may be different 
in the South East Asian population. Yip set out to establish if there was a 
difference in the frequency and severity of ocular complications between 
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Caucasian and Asian patients-both acutely and in the long term. The study 
was a retrospective case study of 117 patients. Only 44 had a follow up of six 
months; thus, the chronic complications were only described in 44 patients. 
The cases of patients seen between 1993 and 2002 were reviewed, and only 
patients with known ocular involvement were included. Patients with a 
minimum of six months follow-up were reviewed for late complications. Ocular 
involvement was defined as mild, moderate and severe. Mild involvement 
consisted of lid oedema and/or mild conjunctival injection and/or chemosis 
only. Moderate involvement comprised membranous conjunctivitis and/or 
corneal epithelial defects and/or corneal ulceration and/or corneal infiltrates. 
Severe involvement comprised symblepharon formation and/or non-healing 
corneal epithelial defects and/or visual loss and/or conjunctival fornix 
shortening. The most common chronic complication was dry eye syndrome 
and trichiasis. Therefore, I included dry eye symptoms as an outcome 
measure in my study. 
The authors found that patients treated with topical antibiotics were likely to 
develop chronic complications-especially dry eyes. They found no difference 
between the acute eye involvement and late complications between patients 
with SJS and TEN. Similar to other authors, they concluded that the severity 
of acute ocular involvement in SJS and TEN does not predict late 
complications. They further concluded that early intervention might prevent 
chronic complications from affecting the external ocular structures. 
Gueudry and others also examined risk factors and predictors for developing 
late ocular complications in SJS and TENs in a retrospective study conducted 
in France on patients seen between 1994 and 2002. There were 117 patients, 
of whom 49 had chronic ocular involvement due to SJS or TEN. They 
described the acute and late ocular manifestations as mild, moderate and 
severe. Mild ocular involvement consisted of eyelid oedema and/or mild 
conjunctival injection and/or chemosis only. Moderate involvement consisted 
of membranous conjunctivitis and/or corneal epithelial defects, with more than 
30% healing with medical treatment and/or corneal ulceration and/or corneal 
infiltrates. Severe involvement consisted of symblepharon formation and/or 
non-healing corneal epithelial defects and/or visual loss and/or conjunctival 
fornix shortening. Each patient had an ophthalmic examination and had to 
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complete an ocular surface disease index (OSOI) questionnaire to determine 
the extent of his or her chronic ocular symptoms. The OSOI questionnaire 
was used to ascertain the severity of dry eye syndrome. This was used by the 
authors following reports that patients who suffered from SJS or TEN had dry 
eye syndrome as a chronic complication of the disease. This further 
strengthened my decision to add dry eyes to my study. There were 129 
patients with acute involvement of their eyes, and 61 of these patients 
completed the OSOI questionnaire. Of these 61 patients, 49 had an 
ophthalmic examination, which provided data for the study. Ory eye syndrome 
and subconjunctival fibrosis were the most common chronic complications. 
Even patients without acute ocular involvement developed dry eye syndrome. 
The authors concluded that all patients with SJS and TEN should receive an 
initial ophthalmological assessment, and that these patients require close 
follow-up. They also stated that ocular medications with preservatives should 
be avoided, as preservatives are known to cause ocular surface disease, 
which can worsen the chronic ocular complications of SJS and TEN. 
In a related article, Yip showed that, despite highly sophisticated 
interventions, patients develop chronic ocular involvement in SJS and TEN 
regardless of whether they are treated in the acute stage.7 This was a small 
retrospective study of 10 patients that compared the outcomes of patients 
receiving high-dose intravenous immuno-globulin with those who did not. The 
study concluded that high-dose intravenous immuno-globulin did not seem to 
reduce the severity of visually significant ocular complications in patients with 
SJS and TEN. 
The previous three articles prove that acute complications, or a lack thereof, 
are not predictors of the severity of chronic ocular complications. The authors 
recommended that patients with SJS or TEN, regardless of the treatment in 
the acute phase, should be followed-up closely, as there is a high likelihood of 
developing chronic ocular complications. 
In contrast to the previous three studies, a case study of three child patients 
with SJS and TEN with acute and chronic ocular complications was presented 
by Gotz-Wieckowska.8 The children were aged between six and 12 years. 
Two of the cases received early ophthalmological intervention by giving the 
children symblepharon massages, steroids and artificial tears. According to 
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the authors, the outcomes of the treatments were excellent. In the latter case, 
where the child did not receive early ophthalmological intervention, the patient 
developed severe chronic ocular disease. This included ocular surface 
neovascularisation and posterior lid keratinisation. According to the authors, 
the results of the treatment were not satisfactory. The authors concluded that 
early intervention in children with SJS and TEN may prevent chronic ocular 
surface complications. Even though this is a small comparative case study, it 
highlights the need for a study to examine the natural history and progression 
of acute ocular complications into chronic complications. 
Due to the high prevalence of HIV infection in South Africa and recent reports 
of the high numbers of SJS and TEN due to Nevirapine and Co-trimoxasole, I 
found it relevant to search for the ocular complications of patients with AIDS 
who had SJS and TEN. There is little literature on the subject, and the only 
relevant article was by Belfort in 1991, who presented a case report on one 
patient with AIDS and TEN, and two patients with AIDS and SJS.9 The 
patients developed severe dry eye symptoms, which were exacerbated by 
HIV-related lacrimal gland dysfunction. They were initially misdiagnosed as 
severe infectious kerato-conjunctivitis. The authors concluded that all 
cicatrising muco-cutaneous reactions should be treated correctly, and that 
patients with dry eyes should be treated to control chronic complications. It is 
not surprising that a condition that causes ocular mucous membrane damage, 
such as SJS and TEN, can exacerbate dry eye symptoms in HIV/AIDS, which 
in itself causes dry eye syndrome. 
In conclusion, very few studies focus solely on chronic ocular complications 
and the incidence thereof in SJS and TEN. All of the above studies described 
patients with confirmed ocular disease. Patients were seen and treated by 
ophthalmologists before participating in the studies. None of the studies took 
a sample of patients with SJS and TEN, with or without confirmed ocular 
disease, to describe the prevalence of ocular surface disease after the 
dermatological lesions have healed. 
There is a need to identify patients from the onset of SJS and TEN and to 
document and follow-up with these patients to monitor ocular complications. 
This would create a better understanding of the natural history of the disease 
and its ocular complications. 
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A limitation in the current literature is that no studies have been conducted in 
Africa. As Yip postulated that there might be differences in the severity of 
ocular disease in different races, it is important to conduct a study on African 
patients to assess the severity of ocular complications. 
There does not appear to be a universal system of grading the chronic 
complications of SJS and TEN, and each author used his or her own 
classification. The adoption of a universal classification wilt bring it into line 
with other disease entities that have an internationally recognised 
classification system. This will better predict the visual prognosis and type of 
treatment that the patient might require. Further, it will be easier to compare 
outcomes in different studies. 
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Purpose: The objective of the study is to identify and grade the severity of 
chronic ocular complications in patients who suffered from Stevens-Johnson 
syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) and were treated at 
Groote Schuur Hospital in Cape Town, South Africa. 
Design: Prospective cross-sectional study. 
Method: A cohort of 52 consecutive patients (104 eyes) with a confirmed 
dermatological diagnosis of SJS or TEN for six months or longer was 
examined. The ocular complications were broadly classified into corneal, 
eyelid and conjunctival complications according to Sotozono's proposed 
classification system. The complications were graded from 0 to 3 depending 
on the severity. 
Main Outcome Measures: These were classified into: 
1. Corneal complications (superficial punctate keratopathy, epithelial defects, 
loss of the palisades of Vogt (POV), conjunctivalisation, neovascularisation, 
opacification and keratinisation) 
2. Eyelid complications (trichiasis, mucocutaneous junction involvement, 
meibomian gland involvement, punctal damage) 
3. Conjunctival complications (hyperaemia, symblepharon formation). 
Results: A total of 108 eyes of 54 patients were included in the study. There 
were 28 males and 26 females. Medications caused SJS or TEN in all cases, 
and the most common associated drugs were: antibiotics (28%), anti-retroviral 
(34%) and anti-epileptic (22%) medications. Almost 60% (59.3%) of patients 
were HIV-positive, with CD4 counts ranging from six to 521 at the time of the 
dermatological diagnosis. Although only 11 % of patients with SJS or TEN had 
acute ocular complications during the initial illness, 89% developed chronic 
ocular complications. Loss of the Pallisades of Vogt (POV) (85.2% (95% 
confidence intervals (Cis) 75.4-95.0%)) was the most common corneal 
complication, followed by superficial punctate keratopathy (SPK) of the 
corneal surface (40.7% (27.2-54.3%)). Among the six components of 
conjunctival and eyelid complications, a mild irregularity of the 
mucocutaneous junction abnormalities (79.6% (CI 68.5-90.7)) was the most 
35 
common, followed by mild conjunctival hyperaemia. There was no statistically 
significant difference in the severity of chronic ocular complications between 
HIV-positive and HIV-negative patients (p=0.4). In addition, the severity of 
chronic ocular complications was not statistically significantly associated with 
visual acuity loss (p=0.3). 
Conclusion: We conclude that almost 90% of patients who are diagnosed 
with SJS or TEN will develop chronic ocular complications. Unless eyelids are 
severely affected, most chronic complications are mild to moderate ocular 
surface abnormalities and not necessarily vision-threatening complications. 
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Introduction 
Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are 
complex immunological syndromes that is characterised by mucocutaneous 
blistering of the skin and at least two mucous membranes. 1,2 Both are part of 
the same disease entity and differ only in severity. A typical lesion has the 
appearance of a target; this is considered pathognomonic. Males are affected 
more than females, and it can occur at any age.3,4 The disease is thought to 
be either a delayed hypersensitivity reaction to certain medications or a 
response to epithelial cell antigens modified by drug exposure. 3,4 Genetic 
predisposition may also playa part due to a genetically determined enzyme 
deficiency for the metabolites of certain medicines.2,3,5 
According to certain studies, 27-80% of cases progress to severe ocular 
disease during the acute dermatological disease. Ocular complications of SJS 
and TEN during the acute phase include conjunctival ch~mosis, conjunctival 
and corneal epithelial defects, corneal ulceration, corneal perforation, 
endophthalmitis and membrane formation. 
It is not clear whether early intervention in the acute stages of SJS and TEN 
will limit ocular complications in future. Further, it is not known why patients 
who have no ocular involvement in the acute stages of SJS or TEN develop 
chronic ocular complications after the dermatological disease has ceased. 
Treatment of acute ocular manifestations usually begins with aggressive 
lubrication of the ocular surface. Most ophthalmologists use topical steroids, 
antibiotics and symblepharon lysis as inflammation and cicatricial changes 
ensue.s 
The aim of the study is to identify the proportion of patients who develop long-
term ophthalmic complications regardless of acute ocular involvement and 
treatment. The study was conducted at Groote Schuur Hospital in Cape 
Town, South Africa. Most of the study participants were indigenous black 
African and mixed-race patients, and most came from areas in Cape Town 
with low socio-economic circumstances and a high prevalence of HIV. No 
other studies have compared chronic ocular complications on HIV-positive 
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and HIV-negative patients resulting from SJS and TEN. The aim was to see if 
HIV infection affects the long-term outcomes of ocular complications resulting 
from SJS and TEN. 
The extent and severity of chronic ocular manifestations were graded. Clinical 
involvements of the external ocular structures were graded according to the 
new grading system formulated by Sotozono et al. 
Methods 
Patients with a confirmed dermatological diagnosis of SJS and TEN were 
recruited from a database from the Department of Dermatology at Groote 
Schuur Hospital. A total of 54 consecutive living patients diagnosed between 
January 2003 and November 2009 were recruited for the study. 
Participants included patients with a dermatological diagnosis of SJS or TEN 
that were admitted and treated for their dermatological disease at Groote 
Schuur Hospital with a follow-up of six months or longer. In addition, both 
eyes of patients were included, even if there was no clinical evidence of 
involvement. Patients were excluded if they had any previous eyelid or ocular 
surface surgery or refused recruitment. 
Ethical approval was granted by the University of Cape Town Faculty of 
Health Sciences Ethics Committee. 
The medical history, ophthalmic examination findings, HIV status and CD4 
count of each patient, as well as their medical history, was captured on an 
itemised data collection form. The degree of involvement was classified into 
13 components of three categories: Corneal (Table 1), Conjunctival and 
Eyelid complications (Table 2). 
A score of 0 to 3 reflected increasing severity, with 0 representing no 
involvement (Table 3 and Table 4). 
Tear break-up times were measured for each eye, and the tear film stability 
was assessed. Each eye was graded, and a score representing the total of 
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the sub-scores was assigned. This severity score could therefore range from 
o to 39, with 39 representing the worst affected. 
Data were analysed using Stata version 11.1 (StataCorp LP, 4905 Lakeway 
Drive College Station, TX 77845 USA). Normality of the data was estimated 
using the Shapiro-Wilk Test. Medians, ranges and interquartile ranges (laR) 
were estimated for non-normally distributed variables. Proportions and 95% 
confidence intervals (Cis) were estimated adjusting for clustering by patient 
where both eyes were analysed. The non-parametric Wilcoxon rank sum 
(Mann-Whitney) test was used to compare two medians, and the Kruskal-
Wallis test was used when three or more medians were compared, because 
the data for eyes were clustered by patients. Somers-D p-values were used. 
The non-parametric Spearman's correlation coefficient was used to estimate 
the relationship between two scores. 
Results 
A total of 108 eyes of 54 patients were included in the study. There were 28 
males and 26 females. The median age at diagnosis was 37 years and 
ranged between 12 and 74 years, the laR was 26 to 47 (Graph 1). 
Medications were the cause in all cases. The most common associated drugs 
were: antibiotics (28%), anti-retroviral (34%) and anti-epileptic (22%) 
medications. Thirty-two (59.3%) patients were HIV-positive, with CD4 counts 
ranging between six and 521 (median 171.5 and laR of 112-202) at the time 
of dermatological diagnosis. 
Only six patients (11 %) needed initial consultation and treatment by an 
ophthalmologist in the acute phase because of epithelial or conjunctival 
defects. However, six months or more after the initial presentation, 46 (85.2%) 
patients had developed chronic ocular complications. 
Of the seven components of corneal complications, the loss of Pallisades of 
Vogt (POV) was the most common (85.2% (95%CI 75.4-95.0)). In most 
cases, loss of more than half of the circumference of the POV were noted. 
Superficial punctate keratopathy (SPK) was present in 81.2% of cases, and 
could most likely be attributed to the instability of the tear film. 
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Among the six components of conjunctival and eyelid complications, mild 
mucocutaneous junction abnormalities were the most common, with 79.6% 
(9S%CI 68.5-90.7) of patients affected, followed by mild conjunctival 
hyperaemia at 40.7% (9S%CI 31.S-S0.6). Nine patients (17%) in the cohort 
had moderate to severe lid complications, which included trichiasis and 
mucocutaneous junction abnormalities. These patients' severity scores 
ranged between 19 and 29 and were the worst affected visually, with visual 
acuities ranging from 6/24 to counting fingers. These nine patients had 
extensive corneal opacification, which accounted for the low final visual 
aquity. Even though there was no statistically significant (p= 0.07, Spearman's 
rho=0.8) correlation between the extent of corneal complications and the 
eyelid abnormalities, there was clinical significance between the extent of 
eyelid complications and corneal opacification. 
The overall severity scores ranged between 0 and 29, the median score was 
9 and the laR was 2.0-12.S. Despite the high percentage of chronic ocular 
complications, most patients had good visual acuities ranging from 6/6 to 
6/18, with an average visual acuity of 6/13.4. The average visual acuity of the 
six patients who were assessed by an ophthalmologist for their acute ocular 
complications was 6/12.1. The average visual acuity of the patients who were 
not assessed by an ophthalmologist in the acute stages was 6/11.4 and was 
not statistically significant (p=0.04S). 
The severity scores were worse in females compared with males (medians 
and laRs 3.S (2.0-8.0) compared with 4.S (3.0-11.0) respectively (Graph 2), 
but these differences were not statistically significant (Wilcoxon rank sum test 
z=-2.33, Somers-D p=0.09). 
There was no statistically significant difference between severity scores 
between HIV-positive and HIV-negative patients (Wilcoxon rank sum test z=-
0.87, Somers-D p=0.S4). Further, by restricting the analysis to only HIV-
infected patients, no statistically significant difference was found in severity 
scores by CD4 category «200, 200-349, 3S0+, Kruskal-Wallis chi-squared 
test=1.09 with 2 d.f. Somers-D p=0.4). (Graph 3) 
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Discussion 
External ocular complications due to SJS and TEN are associated with severe 
visual morbidity. Around 27-80% of hospitalised patients with SJS and TEN 
develop acute ocular complications. 1,2 According to De Rojas, chronic 
complications occur in 35% of patients with SJS and TEN.2 There has been 
no standardised method for the classification of chronic complications of SJS 
and TEN, and each publication in the literature used its own classification 
system. This might have led to an under-estimation of true chronic 
complications, as almost 90% of patients examined in our study had chronic 
complications. We found the classification used by Sotozono useful in the 
analysis of our results. However, we added tear break-up time to the 
classification for comparison with other studies.3,4,5,7 
This study confirmed previous findings that the severity of acute external 
ocular complications does not predict chronic complications.5,s Of the 11 % of 
patients in our study that had an initial ophthalmological assessment, all had 
chronic complications but were not necessarily the worst affected of all 
participants. Our study thus confirms that acute ocular involvement may give 
rise to significant chronic complications, but it should only be regarded as a 
risk factor. 
All patients received preserved lubrication during the acute phase of their 
treatment. It is possible that preservatives may cause ocular surface damage 
and consequently may have increased the incidence of chronic 
complications.7 
This is the first study of its kind that has compared the outcomes of patients 
who were HIV-positive and HIV-negative in Africa. As HIV-positive patients 
have a high prevalence of dry eye syndrome, it was not surprising that 81% of 
patients in this study had SPK secondary to tear film instability. This 
proportion was higher than previously reported.5,7We found there was no 
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statistically significant difference between tear break-up times between HIV-
positive and HIV-negative patients (p=O.98). 
The management of chronic ocular complications due to SJS and TEN should 
be directed at minimising ocular surface inflammation.2 The visual 
rehabilitation in patients with severe ocular involvement resulting from chronic 
complications is difficult and often frustrating for both the patient and the 
ophthalmologist. 
The study has several weaknesses. Only 54 patients were recruited for the 
study. Several patients were deceased or were not contactable, which might 
have caused a gross underestimation of complications. 
The fact that patients were seen prospectively and the data were not collected 
from case notes makes the recording of data objective and more accurate. All 
patients that were examined were seen by only one ophthalmologist to 
standardise the recording of the chronic complications. However, this is one of 
the largest series of its kind at a single unit. 
We suggest that all patients with SJS and TEN should be on long-term 
lubrication, as most will suffer from dry eye syndrome. All patients should 
have an ophthalmological assessment to initiate chronic medication if 
indicated; however, unless eyelids are severely damaged, specialist 
ophthalmological intervention is unnecessary. Eyelid damage causes corneal 
opacification and is the main cause of visual acuity loss. Further, a 
standardised classification system should be adopted for clinical use and to 
standardise future studies. Continued research is necessary into treatment of 
the acute stages of the disease to prevent long-term complications. 
We conclude that most patients will suffer from a wide variety of chronic 
ocular complications following SJS and TEN. Most complications are ocular 
surface abnormalities and not necessarily vision-threatening complications. 
The loss of Vogt's palisades and dry eye syndrome with SPK were the most 
common complications. Poorer visual outcomes can be expected if there are 
severe eyelid complications. HIV status and low CD4 count was not a risk 
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factor for more severe outcomes. All patients with SJS or TEN should have an 
ophthalmological evaluation regardless of initial non-ocular involvement. 
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Severity of superficial punctuate keratopathy 
1 = Staining of less than a 1/3 of the corneal surface, 
2= Staining of more than a % but less than % of corneal surface 
3= Staining of more than 2/3 of the corneal surface 
Corneal epithelial defect: 
1 = Epithelial defect involving less than 1.4 of the corneal surface 
2= Epithelial defect involving more than 1/4 but less than Y2 of the corneal surface 
3= Epithelial defect involving more than Y2 of the corneal surface 
Loss of the palisades of Vogt (POV): 
1 = Loss of less than 112 of the circumference of the POV, 
2= Loss of more than 112 of the circumference of the POV 
3= Total loss of the circumference of the POV 
Conjunctlvallsatlon: 
1 = Conjunctivalisation involving less than Y4 of the corneal surface 
2= Conjunctivalisation involving more than Y4 but less than Y2 of the corneal surface 
3= Conjunctivalisation involving more than Y2 of the corneal surface 
Corneal neovascularlsatlon: 
1 = Neovascularisation confined to the corneal periphery 
2= Neovascularisation extending up to the pupil margin 
3= Neovascularisation extending beyond the pupil margin into the central cornea 
Corneal opacification: 
1 =Partial obscuration of iris details 
2= Iris details poorly seen with pupil margin just visible 
3= Complete obscuration of iris and pupil details 
Corneal keratlnlsatlon: 
1 =Keratinisation involving < Y4 of the corneal surface 
2= Keratinisation involving> 1.4 to Y2 of the corneal surface 





1 =Mild or sectoral engorgement of the conjunctival vessels 
2= Moderate or diffuse engorgement of the conjunctival vessels 
3= Severe hyperaemia or significant engorgement of the conjunctival vessels 
Symblepharon formation: 
1 = Symblepharon formation only involving the conjunctival surface 
2= Symblepharon formation involving < 112 of the corneal surface 
3= Symblepharon formation involving> Y2 of the corneal surface 
Evelid complications: 
Trichiasis: (total area of the upper and lower eyelids combined) 
1= Trichiasis involving less than 1,4 of the lid margin 
2= Trichiasis involving more than 1,4 and less than 112 of the lid margin 
3= Trichiasis involving more than Y2 of the lid margin 
Mucocutaneous junction Involvement: 
1 =Mild Irregularity of the mucocutaneous junction 
2=Moderate irregularity of the mucocutaneous junction 
3=Severe irregularity of the mucocutaneous junction 
Meibomian gland involvement: 
1 = Yellowish-white oily fluid expressed 
2= Thick cheesy material expressed 
3= Inability to express any fluid 
Punctallnvolvement: 
1=latrogenic punctual occlusion (e.g. punctal plugs or sutures) 
2=elther superior or inferior puncta occluded by scarring 
3= both superior and inferior puncta occluded by scarring 
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Graph 3: Box plot oj severity scores by HIV status 
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1. Informed consent form 
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I nformed Consent Form 
Stevens-Johnson syndrome and Toxic Epidermal Necrolysis Study 
Prospective Research Subject: Read this consent form carefully. Ask as many 
questions as you like before you decide whether you want to participate in this 
research study. You are free to ask questions at any time before, during, or 
after your participation in this research. 
Project Title: Prevalence of chronic complications in Stevens-Johnson 
syndrome and Toxic Epidermal Necrolysis. 
Principal Researcher: Dr. L.M. van Zyl 
Telephone: 082 875 8630 
E-mail: lourensvz4@gmail.com 
Organization: University of Cape Town 
Location of Study: Groote Schuur Hospital, Ward 04 and Out Patients 
Department 
Purpose of This Research Study 
You are being asked to participate in a research study designed to look at 
what the long term effects are on the visible structures of your eyes. These 
structures include the skin around your eyes, your eyelids, the fleas around 
your eyeball called the conjunctiva and the clear part of your eye called the 
cornea. 
The doctor in charge of this study is Dr. Lourens van Zyl who is a doctor 
studying to become a speCialist eye-doctor. This study will be conducted as 
part of his degree program in a masters degree in medicine at the University 




1 attend an examination session on a specific date where the research 
assistant will test the vision in both your eyes. 
2 be examined by the research doctor with various equipment used by eye 
doctors like an examination microscope called a slit lamp. The doctor will 
put medical drops in your eyes that numb any feeling in that eye. None of 
the examinations will cause you any pain. There might be a slight 
discomfort if you are sensitive to bright light as the equipment uses electric 
light to help the doctor to examine you better. The examination will not 
take longer than 20 minutes. If the doctor feels that you need further 
treatment he will write you a referral letter to an appropriate hospital or 
clinic. 
Possible Risks 
There are no risks involved in participating in this study. 
Possible Benefits 
There is a possibility that if you are affected by the disease that we may 
discover that you might benefit from further treatment to give relief from the 
involvement of your eyes. 
We as doctors might get a better understanding from your disease so that we 
can treat patients more successfully in future. 
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Financial Considerations 
You will receive financial compensation for your participation to cover all your 
travel costs. If you have an escort due to your inability to travel alone, the 
escort will also be compensated. Only a sum total of one escort will be 
compensated and any other companions must incur their own costs. To 
participate in this study it will not cost you as a participant any money. 
Confidentiality 
Your identity in this study will be treated as confidential. Results of the study, 
including all collected data, may be published in the research doctor's 
dissertation and in possible future journal articles and professional 
presentations, but your name or any identifiable references to you will not be 
included. Your hospital number is the only identifiable reference that will be 
used in this study. However, any records or data obtained as a result of your 
participation in this study may be inspected by the persons conducting this 
study and/or the University's Review Board, provided that such inspectors are 
legally obligated to protect any identifiable information from public disclosure, 
except where disclosure is otherwise required by law or a court of competent 
jurisdiction. These records will be kept private in so far as permitted by law. 
Termination of Study 
You are free to choose whether to participate in this study. You may also 
choose to withdraw from the study or to decline to answer any questions at 
any time. You will not be penalized or lose any benefits to which you are 
otherwise entitled if you choose not to participate or choose to withdraw. You 
will be provided with any significant new findings developed during the course 
of this study that may relate to or influence your willingness to continue 
participation. In the event you decide to discontinue your participation in the 
study, please notify Dr. L.M. van Zyl (082 875 8630, 021 404 3526) of your 
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decision so that your participation can be terminated in an orderly fashion. All 
data collected on, about, or by you will be destroyed and not used in the data 
analysis or writing of the findings if you choose to withdraw. 
Resources 
Any questions you may have about this study will be answered by Dr. L.M. 
van Zyl (082 875 8630, 021 4043526, e-mail: lourensvanzyl@hotmail.com) or 
Dr. Karin Lecuona (079 8601377, 021 4043526, e-mail: 
karin Jecuona@uct.ac.za). 
Any questions you may have about your rights as a research subject will be 
answered by the University of Cape Town Research council, 021 4060009 
Subject and Researcher Authorization 
I have read and understand this consent form, and I volunteer to participate in 
this research study. I understand that I will receive a copy of this form. I 
voluntarily choose to participate, but I understand that my consent does not 
take away any legal rights in the case of negligence or other legal fault of 
anyone who is involved in this study. I further understand that nothing in this 
consent form is intended to replace any applicable provincial, state, or 
university laws. 
In case of a minor: I have read and understand this consent form, and I 
voluntarily consent to my child's participation in this research study. I 
understand that my consent does not take away any legal rights in the case of 
negligence or other legal fault of anyone who is involved in this study. I further 
understand that nothing in this consent form is intended to replace any 
applicable provincial, state, or university laws. 
57 
Signatures 
Participant Name (printed): 
Participant Signature: ____________________ _ 
Date: 
Legal Guardian Name (printed): _________________ _ 
Legal Guardian Signature: __________________ _ 
Date: 
Principal Researcher's Name (printed): ______________ _ 
Principal Researcher's Signature: ________________ _ 
Date: 




2. Patient information sheet 
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Patient information sheet 
Patient Sticker 
Age Gender Period after attack 
(months) 




Eye Right Left 
Visual acuity (1: 6/6- 1 2 3 1 2 3 
6/18, 2:6/24- 6/60, 3: <6/60) 
Tonometry 
SPK 1 2 3 1 2 3 
Corneal epithelial 1 2 3 1 2 3 
defect 
Loss of POV 1 2 3 1 2 3 
Conjunctivalisation 1 2 3 1 2 3 
Corneal neovasc'tion 1 2 3 1 2 3 
1 Corneal opacification 11 2 3 2 3 
60 
Corneal 1 2 3 1 2 3 
keratinisation 
Conjunctival 1 2 3 1 2 3 
hyperaemia 
Symblepharon 1 2 3 1 2 3 
formation 
Trichiasis 1 2 3 1 2 3 
Mucocutaneous 1 2 3 1 2 3 
junction involvement 
Meibomian gland 1 2 3 1 2 3 
involvement 
Punctallnvolvement 1 2 3 1 2 3 
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3. Guide to complications 
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Guide to the classification of complications 
Corneal complications: 
Severity of superficial punctuate keratopathy: 
0: No punctuate staining 
1: Staining of < 1/3 of corneal surface 
2: Staining of > 1/3 but < 2/3 of corneal surface 
3: Staining of> 2/3 of corneal surface 
Corneal epithelial defect: 
0: No epithelial defect 
1 : Epithelial defect involving < 1A of the corneal surface 
2: Epithelial defect involving> 1A but < V2 of the corneal surface 
3: Epithelial defect involving> V2 of the corneal surface 
Loss of the palisades of Vogt (POV): 
0: Presence of the entire POV 
1 : Loss of < V2 of the circumference of the POV 
2: Loss of > V2 of the circumference of the POV 
3: Total loss of the circumference of the POV 
Conjunctivalisation: 
0: Absence of conjunctivalisation 
1: Conjunctivalisation involving < 1A of the corneal surface 
2: Conjunctivalisation involving> 1A but < V2 of the corneal surface 
3: Conjunctivalisation involving> V2 of the corneal surface 
Corneal neovascularisation: 
0: No neovascularisation 
1 : Neovascularisation confined to the corneal periphery 
2: Neovascularisation extending up to the pupil margin 
3: Neovascularisation extending beyond the pupil margin into the central 
cornea 
In eyes with significant opacification and symblepharon with difficulty in 
evaluating corneal neovascularisation a score of 3 will be assigned 
Corneal opacification: 
0: Clear cornea with iris details clearly visible 
1: Partial obscuration of iris details 
2: Iris details poorly seen with pupil margin just visible 
3: Complete obscuration of iris and pupil details 
Corneal keratinisation: 
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0: No keratinisation 
1: Keratinisation involving < ~ of the corneal surface 
2: Keratinisation involving > ~ to V2 of the corneal surface 
3: Keratinisation involving> V2 of the corneal surface 
Conjunctival complications: 
Conjunctival hyperaemia: 
0: Absence of hyperaemia 
1 : Mild or sectoral engorgement of the conjunctival vessels 
2: Moderate or diffuse engorgement of the conjunctival vessels 
3: Severe hyperaemia or significant engorgement of the conjunctival vessels 
Symblepharon formation: 
0: No symblepharon 
1: Symblepharon formation only involving the conjunctival surface 
2: Symblepharon formation involving < V2 of the corneal surface 
3: Symblepharon formation involving> V2 of the corneal surface 
Eyelid complications: 
Trichiasis: (total area of the upper and lower eyelids combined) 
0: No trichiasis 
1 : Trichiasis involving < ~ of the lid margin 
2: Trichiasis involving > ~ and < V2 of the lid margin 
3: Trichiasis involving> V2 of the lid margin 
Mucocutaneous junction involvement: 
0: Normal mucocutaneous junction 
1 : Mild irregularity of the mucocutaneous junction 
2: Moderate irregularity of the mucocutaneous junction 
3: Severe irregularity of the mucocutaneous junction 
In eyes with significant keratinisation of the lid margin or extensive 
symblepharon where evaluation of the lid margin is difficult, a score of 3 will 
be given 
Meibomian gland involvement: 
64 
The severity of meibomian gland involvement is determined clinically by the 
nature of the gland excretion expressed manually at the centre of the upper lid 
0: Clear oily fluid expressed 
1: Yellowish-white oily fluid expressed 
2: Thick cheesy material expressed 
3: Inability to express any fluid 
Punctal involvement: 
0: Normal patent puncta 
1: Iatrogenic punctal occlusion (e.g. punctual plugs or sutures) 
2: Either superior or inferior puncta occluded by scarring 
3: Both superior and inferior puncta occluded by scarring 
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